



Pioglitazone

Catalog No: tcsc1700

Available Sizes
Size: 10mg
Size: 50mg
Specifications
CAS No: 111025-46-8
Formula: C ₁₉ H ₂₀ N ₂ O ₃ S
Pathway: Cell Cycle/DNA Damage
Target: PPAR
Purity / Grade: >98%
Solubility: H2O :
Alternative Names: U 72107
Observed Molecular Weight: 356.44

Product Description

Pioglitazone is a potent and selective **PPAR** γ agonist with high affinity binding to the PPAR γ ligand-binding domain with **EC**₅₀ of 0.93 and 0.99 μ M for human and mouse PPAR γ , respectively.





IC50 & Target: EC50: 0.93 μ M (human PPAR γ), 0.99 μ M (mouse PPAR γ)^[1]

In Vitro: AGEs-induced beta cell necrosis is completely abrogated by adding Pioglitazone to the AGEs culture medium. Furthermore Pioglitazone completely prevented any AGEs-induced increment in caspase-3 activation, thereby restoring caspase-3 activity to the same levels as the control cells. As expected AG is able to counteract AGEs-induced impaired viability^[2].

In Vivo: The serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and $adipo^{-/-}$ ob/ob mice are unchanged after 10 mg/kg Pioglitazone but are significantly reduced to a similar degree after 30 mg/kg Pioglitazone. Moreover, the expressions of TNF α and resistin in adipose tissues of ob/ob and $adipo^{-/-}$ ob/ob mice are unchanged after 10 mg/kg Pioglitazone but are decreased after 30 mg/kg Pioglitazone. Thus, Pioglitazone-induced amelioration of insulin resistance and diabetes may occur adiponectin dependently in the liver and adiponectin independently in skeletal muscle^[3]. Pioglitazone (10 mg/kg per d) treatment significantly attenuates the loss of body weight (BW) and cardiac hypertrophy. Pioglitazone treatment significantly reduces the elevated serum glucose levels and markedly improved the associated dyslipidemia. Furthermore, there is a slight but significant increase in serum creatinine level in D rats over their N controls (P [4].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!